Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XENE |
---|---|---|
09:32 ET | 1120 | 40.35 |
09:50 ET | 100 | 40.37 |
09:52 ET | 416 | 40.33 |
09:56 ET | 100 | 40.56 |
09:59 ET | 1262 | 40.4214 |
10:06 ET | 152 | 40.47 |
10:10 ET | 800 | 40.435 |
10:15 ET | 200 | 40.43 |
10:17 ET | 608 | 40.265 |
10:24 ET | 148 | 40.2388 |
10:26 ET | 1340 | 40.19 |
10:28 ET | 665 | 40.06 |
10:32 ET | 199 | 40.147 |
10:35 ET | 100 | 40.01 |
10:39 ET | 215 | 40.075 |
10:44 ET | 1416 | 40.11 |
10:46 ET | 100 | 40.04 |
10:48 ET | 3826 | 39.98 |
10:50 ET | 600 | 40 |
10:53 ET | 300 | 39.985 |
10:55 ET | 427 | 39.965 |
10:57 ET | 100 | 39.94 |
11:00 ET | 200 | 39.95 |
11:02 ET | 118 | 39.968 |
11:04 ET | 300 | 39.96 |
11:06 ET | 500 | 39.91 |
11:22 ET | 175 | 39.9102 |
11:24 ET | 600 | 39.92 |
11:26 ET | 520 | 39.91 |
11:27 ET | 1200 | 39.9968 |
11:31 ET | 600 | 39.91 |
11:36 ET | 1910 | 39.94 |
11:42 ET | 300 | 39.955 |
11:44 ET | 300 | 39.945 |
11:45 ET | 100 | 39.945 |
11:47 ET | 100 | 39.89 |
11:49 ET | 523 | 39.9599 |
11:54 ET | 500 | 39.89 |
11:58 ET | 100 | 39.985 |
12:00 ET | 100 | 39.9511 |
12:02 ET | 100 | 39.99 |
12:03 ET | 900 | 39.98 |
12:05 ET | 625 | 39.98 |
12:09 ET | 1660 | 40.065 |
12:12 ET | 3200 | 40.11 |
12:14 ET | 100 | 40.11 |
12:16 ET | 602 | 40.114 |
12:18 ET | 1688 | 40.03 |
12:23 ET | 3150 | 40.105 |
12:25 ET | 100 | 40.07 |
12:34 ET | 300 | 40.07 |
12:36 ET | 700 | 40.05 |
12:38 ET | 228 | 40.095 |
12:39 ET | 272 | 40.1 |
12:43 ET | 1149 | 40.04 |
12:45 ET | 100 | 40.04 |
12:54 ET | 2018 | 40 |
12:56 ET | 953 | 40.02 |
12:57 ET | 695 | 40.005 |
01:03 ET | 200 | 40.04 |
01:06 ET | 100 | 40 |
01:10 ET | 200 | 40.01 |
01:12 ET | 200 | 40.02 |
01:14 ET | 100 | 40 |
01:15 ET | 400 | 39.99 |
01:17 ET | 168 | 40 |
01:19 ET | 670 | 39.955 |
01:21 ET | 100 | 39.92 |
01:28 ET | 533 | 39.86 |
01:30 ET | 100 | 39.8 |
01:33 ET | 300 | 39.78 |
01:35 ET | 300 | 39.75 |
01:37 ET | 1500 | 39.82 |
01:39 ET | 100 | 39.805 |
01:42 ET | 300 | 39.83 |
01:44 ET | 216 | 39.79 |
01:46 ET | 200 | 39.885 |
01:48 ET | 100 | 39.835 |
01:50 ET | 300 | 39.835 |
01:51 ET | 500 | 39.9 |
01:53 ET | 100 | 39.88 |
01:55 ET | 500 | 39.86 |
02:02 ET | 576 | 39.87 |
02:04 ET | 100 | 39.83 |
02:06 ET | 100 | 39.8 |
02:08 ET | 500 | 39.78 |
02:11 ET | 100 | 39.73 |
02:18 ET | 1224 | 39.7 |
02:22 ET | 300 | 39.68 |
02:24 ET | 400 | 39.6 |
02:26 ET | 400 | 39.64 |
02:27 ET | 300 | 39.67 |
02:31 ET | 300 | 39.81 |
02:33 ET | 549 | 39.73 |
02:38 ET | 300 | 39.67 |
02:40 ET | 200 | 39.6975 |
02:42 ET | 200 | 39.72 |
02:45 ET | 100 | 39.69 |
02:47 ET | 300 | 39.69 |
02:49 ET | 500 | 39.65 |
02:51 ET | 100 | 39.66 |
02:54 ET | 645 | 39.66 |
02:56 ET | 100 | 39.665 |
03:02 ET | 600 | 39.63 |
03:03 ET | 100 | 39.6 |
03:05 ET | 600 | 39.645 |
03:12 ET | 1416 | 39.71 |
03:14 ET | 200 | 39.68 |
03:16 ET | 597 | 39.52 |
03:18 ET | 2355 | 39.5 |
03:20 ET | 100 | 39.49 |
03:21 ET | 1713 | 39.545 |
03:23 ET | 808 | 39.61 |
03:27 ET | 1206 | 39.59 |
03:30 ET | 385 | 39.55 |
03:32 ET | 500 | 39.54 |
03:34 ET | 600 | 39.5 |
03:36 ET | 500 | 39.51 |
03:38 ET | 900 | 39.53 |
03:39 ET | 816 | 39.55 |
03:41 ET | 1540 | 39.57 |
03:43 ET | 1603 | 39.56 |
03:45 ET | 9787 | 39.7723 |
03:48 ET | 5100 | 39.75 |
03:50 ET | 864 | 39.84 |
03:52 ET | 1903 | 39.75 |
03:54 ET | 2927 | 39.84 |
03:56 ET | 3475 | 39.8 |
03:57 ET | 1634 | 39.875 |
03:59 ET | 5769 | 39.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Xenon Pharmaceuticals Inc | 3.0B | -14.7x | --- |
Apogee Therapeutics Inc | 2.9B | -24.6x | --- |
Summit Therapeutics Inc | 3.1B | -26.8x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Iovance Biotherapeutics Inc | 2.9B | -5.6x | --- |
IDEAYA Biosciences Inc | 3.1B | -20.2x | --- |
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.23 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -14.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.